2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
作者： Désirée van der Heijde , Joachim Sieper , Walter P Maksymowych , Maxime Dougados , Rubén Burgos-Vargas
关键词:
摘要: This paper presents the second update of the Assessment in SpondyloArthritis international Society (ASAS) consensus statement on the use of anti-tumour necrosis factor (anti-TNF) …
core.ac.uk
narcis.nl参考文章(17)
Sjef Van Der Linden, Hans A. Valkenburg, Arnold Cats, Evaluation of Diagnostic Criteria for Ankylosing Spondylitis Arthritis & Rheumatism. ,vol. 27, pp. 361- 368 ,(1984) , 10.1002/ART.1780270401
Nick Barkham, Helen I. Keen, Laura C. Coates, Philip O'Connor, Elizabeth Hensor, Alexander D. Fraser, Lorna S. Cawkwell, Alexander Bennett, Dennis McGonagle, Paul Emery, Clinical and imaging efficacy of infliximab in HLA–B27–Positive patients with magnetic resonance imaging–determined early sacroiliitis Arthritis & Rheumatism. ,vol. 60, pp. 946- 954 ,(2009) , 10.1002/ART.24408
D�sir�e van der Heijde, Herbert S. B. Baraf, Cesar Ramos-Remus, Andrei Calin, Arthur L. Weaver, Michael Schiff, Margaret James, Jan E. Markind, Alise S. Reicin, Agustin Melian, Maxime Dougados, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis & Rheumatism. ,vol. 52, pp. 1205- 1215 ,(2005) , 10.1002/ART.20985
Désirée van der Heijde, Robert Landewé, Xenofon Baraliakos, Harry Houben, Astrid van Tubergen, Paul Williamson, Weichun Xu, Daniel Baker, Neil Goldstein, Jürgen Braun, , Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis & Rheumatism. ,vol. 58, pp. 3063- 3070 ,(2008) , 10.1002/ART.23901
Martin Rudwaleit, Hildrun Haibel, Xenofon Baraliakos, Joachim Listing, Elisabeth Märker-Hermann, Henning Zeidler, Jürgen Braun, Joachim Sieper, The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis & Rheumatism. ,vol. 60, pp. 717- 727 ,(2009) , 10.1002/ART.24483
Hildrun Haibel, Martin Rudwaleit, Joachim Listing, Frank Heldmann, Robert L. Wong, Hartmut Kupper, Jürgen Braun, Joachim Sieper, Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two† Arthritis & Rheumatism. ,vol. 58, pp. 1981- 1991 ,(2008) , 10.1002/ART.23606
D Van der Heijde, R Landewe, S Einstein, P Ory, D Vosse, L Ni, S‐L Lin, W Tsuji, JC Davis Jr, None, Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis & Rheumatism. ,vol. 58, pp. 1324- 1331 ,(2008) , 10.1002/ART.23471
J Braun, T Pham, J Sieper, J Davis, SJ Van der Linden, M Dougados, D Van der Heijde, None, International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Annals of the Rheumatic Diseases. ,vol. 62, pp. 817- 824 ,(2003) , 10.1136/ARD.62.9.817
D E Furst, E C Keystone, J Braun, F C Breedveld, G R Burmester, F De Benedetti, T Dörner, P Emery, R Fleischmann, A Gibofsky, J R Kalden, A Kavanaugh, B Kirkham, P Mease, J Sieper, N G Singer, J S Smolen, P L C M Van Riel, M H Weisman, K Winthrop, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 Annals of the Rheumatic Diseases. ,vol. 69, pp. 2- 29 ,(2006) , 10.1136/ANNRHEUMDIS-2011-201036
H Whitelock, A Calin, P Gaisford, S Garrett, L G Kennedy, T Jenkinson, A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. ,vol. 21, pp. 2286- 2291 ,(1994)